Finerenone Use in Coenzyme Q8B–Related Focal Segmental Glomerulosclerosis Authors: Manaf Aljishi, Mohamed Khogali, Turki Alhussain, Tofol Alnashmi Published: 2026 ABSTRACT Genetic focal segmental glomerulosclerosis (FSGS) caused by mutations affecting coenzyme Q (CoQ) biosynthesis is a rare podocytopathy that is associated with poor response to immunosuppression. Finerenone is a nonsteroidal mineralocorticoid antagonist that reduces oxidative stress, glomerular inflammation, and fibrosis, features seen in CoQ deficiency. We report the first case of its use in COQ8B-related FSGS. A 35-year-old woman was evaluated for persistent postpartum proteinuria and underwent a kidney biopsy that showed features of FSGS. She had a strong family history of early-onset kidney failure. She had no response to corticosteroids, tacrolimus, and empgagliflozin. Genetic testing revealed a homozygous COQ8B mutation. CoQ10 supplementation was not tolerated. Finerenone was initiated in May 2024, with significant improvement in albuminuria from 6,460 mg/g to 1,430 mg/g after 12 months and a slowing of the decline in estimated glomerular filtration rate from -9.55 mL/min/1.73 m2/y to -6.77 mL/min/1.73 m2/y. There was only mild transient hyperkalaemia. It was stopped after 12 months owing to hypotension, and by 6 months, the proteinuria increased to 4,860 mg/g and creatinine increased from 1.56 mg/dL to 2.22 mg/dL. This case suggests a potential role for finerenone as adjunctive therapy in genetic FSGS. Introduction Focal segmental glomerulosclerosis (FSGS) is the leading cause of glomerulonephritis that affects up to 40% of adults with nephrotic syndrome. It is characterized by progressive proteinuria, nephrotic syndrome, and kidney dysfunction, leading to end-stage kidney disease. Recent advances in genetic sequencing and genetic linkage studies have identified genetic variants linked to FSGS in ∼30% of steroid-resistant nephrotic syndrome.1,2 These include mutations in mitochondrial proteins that contribute to the synthesis of coenzyme Q (CoQ)10, a key molecule for mitochondrial energy production. Because podocytes are highly active and dependent on aerobic metabolism, these mutations lead to cytoskeletal instability, detachment from the glomerular basement membrane, disruption of the slit diaphragm structure, resulting in proteinuria, and FSGS.3 Response to conventional immunosuppression is typically limited. CoQ10 supplementation targets the primary metabolic defect and has been shown to reduce proteinuria and kidney function decline.4 However, it is limited by a number of factors—the low and variable absorption and the gastrointestinal side effects.5,6 Mineralocorticoid receptor activation has been implicated in podocyte damage through oxidative stress, inflammation, and profibrotic signaling in the kidney,7 which are features seen in CoQ deficiency.8,9 Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist that has been shown to reduce oxidative stress with potent anti-inflammatory and antifibrotic effects.10,11 It has demonstrated renoprotective effects in diabetic kidney disease.12 However, its role in hereditary podocytopathies is not reported. In this study, we report, to our knowledge, the first case of using finerenone in genetic FSGS. Case Presentation A 35-year-old Saudi woman was referred for persistent proteinuria in January 2022, which was first detected during her first pregnancy in 2017. The patient had pre-eclampsia at that time, but proteinuria persisted postpartum and did not resolve. She had no past medical history and no exposure to nephrotoxins. She was a nonsmoker. Her family history was notable for 2 siblings with early-onset kidney failure. Her brother, currently aged 49 years, developed kidney disease in early adulthood and underwent kidney transplantation at the age of 34 years. Her sister, currently aged 47 years, also received a kidney transplant at the age of 36 years. Her parents and the other 4 siblings had no history of kidney disease. On initial evaluation, her weight was 55.8 kg, with a body mass index of 21.4 kg/m2. Her blood pressure was 116/76 mm Hg, and she had no lower limb edema. Laboratory evaluation showed normal serum creatinine of 76 μmol/L; serum albumin 41 g/L; normal complete blood count except mild chronic leucopenia; and a white blood cell count of 3.39 × 109/L, with neutrophils of 1.90 × 109/L. Urinalysis showed +protein, no hematuria, leukocyturia, or urinary casts. The urinary albumin-creatinine ratio (UACR) was 980 mg/g. Serologic work-up and complement testing, including anti-nuclear antibodies, antineutrophil cytoplasmic antibodies, anti--double-stranded DNA antibodies, complement levels, human immunodeficiency virus type 1, and hepatitis B and C serology, were negative. Hemoglobin A1c was 5.10%. Ultrasonography of the kidneys was unremarkable, with normal kidney size. Treatment with ramipril 10 mg daily (later changed to valsartan 80 mg owing to hypotension) was started in January 2022, and empagliflozin 25 mg was added in May 2022 but failed to significantly reduce proteinuria. Kidney biopsy performed in November 2022 demonstrated 58 glomeruli, of which 28 showed global sclerosis and 3 showed segmental sclerosis. The remaining glomeruli showed mild mesangial expansion and hypercellularity, with normal glomerular basement membrane thickness, patent capillary lumens, and no endocapillary proliferation. There was moderate interstitial fibrosis and tubular atrophy involving ∼40% of the cortical tissue, accompanied by a moderate interstitial mononuclear inflammatory cell infiltrate. Immunofluorescence studies were negative. Electron microscopy revealed no electron-dense deposits, and podocytes demonstrated focal foot process effacement. These findings were consistent with FSGS (Fig 1).Figure 1Kidney biopsy findings. (A) Two glomeruli showing segmental sclerosis (periodic acid–Schiff stain, ×400). (B) A glomerulus showing segmental sclerosis (Jones silver stain, ×200). (C) Interstitial fibrosis and tubular atrophy associated with globally sclerosed glomeruli (trichrome stain, ×100). Kidney biopsy findings. (A) Two glomeruli showing segmental sclerosis (periodic acid–Schiff stain, ×400). (B) A glomerulus showing segmental sclerosis (Jones silver stain, ×200). (C) Interstitial fibrosis and tubular atrophy associated with globally sclerosed glomeruli (trichrome stain, ×100). After the biopsy findings, the patient was treated with a 6-month course of prednisone until June 2023. Tacrolimus (aiming level 5-10 μg/L) was also added from December 2022 until May 2024. However, by October 2023, there was progressive worsening of proteinuria to a UACR of 3,200 mg/g and creatinine of 1.06 mg/dL by March 2024. Given the strong family history and steroid-dependent course, genetic testing was performed. A genetic panel that used next-generation sequencing (Illumina platform; Illumina) identified a missense variant c.532C>T p.(Arg178Trp) in probable homozygosity in exon 7 of 15 of the COQ8B gene. This variant is reported in the ClinVar database (ClinVar ID: 91845).13 Thereafter, a trial of CoQ10 supplementation was initiated but discontinued owing to gastrointestinal intolerance, fatigue, and lethargy. Finerenone was initiated off-label in May 2024 at 10 mg daily and increased to 20 mg daily in November 2024. Her baseline serum creatinine was 1.40 mg/dL (estimated glomerular filtration rate 50 mL/min/1.73 m2), UACR was 6,460 mg/g, and potassium was 4.8 mmol/L. At initiation, blood pressure was 144/107 mmHg, improving to an average of 127/80 mmHg during follow-up (Fig 2).Figure 2Longitudinal trends in kidney function, proteinuria, and serum potassium. (A) Serum creatinine (mg/dL) trend over time, demonstrating a progressive increase with relative stabilization from May 2024 when finerenone was initiated, and rapid progression again from June 2025 after finerenone was stopped. (B) Estimated glomerular filtration rate (in mL/min/1.73 m2), calculated using the Chronic Kidney Disease Epidemiology Collaboration 2021 equation, showing a trajectory corresponding to the serum creatinine trend over the same period. (C) Urinary albumin-to-creatinine ratio (mg/g), illustrating rapid improvement in level in May 2024 when finerenone was started, and a loss of control after it was stopped in November 2025. (D) Serum potassium concentration (mmol/L) showing variability with values largely remaining within clinically acceptable range. Longitudinal trends in kidney function, proteinuria, and serum potassium. (A) Serum creatinine (mg/dL) trend over time, demonstrating a progressive increase with relative stabilization from May 2024 when finerenone was initiated, and rapid progression again from June 2025 after finerenone was stopped. (B) Estimated glomerular filtration rate (in mL/min/1.73 m2), calculated using the Chronic Kidney Disease Epidemiology Collaboration 2021 equation, showing a trajectory corresponding to the serum creatinine trend over the same period. (C) Urinary albumin-to-creatinine ratio (mg/g), illustrating rapid improvement in level in May 2024 when finerenone was started, and a loss of control after it was stopped in November 2025. (D) Serum potassium concentration (mmol/L) showing variability with values largely remaining within clinically acceptable range. Before finerenone, UACR was showing variability, with an overall progressive course. For about 1 year after finerenone initiation, UACR improved from 6,460 to 1,430 mg/g, and demonstrated improvement in levels and relative stabilization for 12 months, indicating a partial response in proteinuria. The estimated glomerular filtration rate declined from 50 mL/min/1.73 m2 before finerenone to 43.9 mL/min/1.73 m2 in June 2026; the slope of the estimated glomerular filtration rate decline improved from -9.55 mL/min/1.73 m2/y before finerenone to -6.77 mL/min/1.73 m2/y, suggesting attenuation of disease progression. Finerenone was generally well tolerated, with a single episode of mild hyperkalemia (serum potassium 5.3 mmol/L) in June 2024 that did not require discontinuation. Owing to partial response, intolerance to CoQ10, and limited alternative options, rituximab (1,000 mg 2 weeks apart) was administered in February 2025 without improvement in proteinuria or kidney function. The patient had symptomatic hypotension, which persisted after stopping valsartan in May 2025, leading to discontinuation of finerenone in June 2025, while remaining only on empagliflozin. Thereafter, trials to reinitiate finerenone failed owing to symptomatic hypotension. Thereafter, serum creatinine increased from 1.56 mg/dL in June 2025 to 2.22 mg/dL in January 2026, and UACR from 1,430 mg/g in June to 2,740 in October and 4,860 mg/g in December 2025 (Fig 2). Discussion This case describes the first report of finerenone use in genetically confirmed FSGS and suggests a possible benefit in attenuating kidney function decline and reducing proteinuria. It also highlights the evolving importance of genetic testing in patients with FSGS, particularly in the presence of a strong family history and suboptimal response to immunosuppressive therapy. To our knowledge, this report represents the first description of finerenone use in a patient with genetically confirmed COQ8B-associated FSGS. The observed attenuation in kidney function decline and partial stabilization of proteinuria in this patient suggest it may have adjunctive therapeutic potential. Because the pathogenic pathways inhibited by finerenone are shared between multiple kidney diseases, there is increasing recent interest and experience in using it for nondiabetic kidney disease and glomerulonephritis, namely immunoglobulin A nephropathy and obesity-related glomerulomegaly.14,15 Recent studies have reported that adding finerenone to standard therapy with renin-angiotensin-aldosterone system and sodium/glucose cotransporter 2 inhibitors significantly reduced albuminuria in patients with nondiabetic chronic kidney disease, without causing significant adverse effects such as hyperkalemia.16 Another real-world retrospective study demonstrated that finerenone significantly reduces albuminuria in nondiabetic chronic kidney disease patients (primarily those with immunoglobulin A and membranous nephropathy) without significantly affecting potassium levels or kidney function over a 12-month period.17 The pivotal phase III Finerenone in Persons with Chronic Kidney Disease without Diabetes (FIND-CKD) trial recently demonstrated efficacy of finerenone in non-diabetic kidney disease at slowing eGFR decline.18,19 Finerenone may be theoretically beneficial in genetic FSGS through its anti-inflammatory and antifibrotic effects, which extend beyond blood pressure and proteinuria reduction.11 Aldosterone-mediated mineralocorticoid receptor signaling increases reactive oxygen species production and accelerates podocyte loss, glomerulosclerosis, and interstitial fibrosis.7 By attenuating these downstream pathways, finerenone may help slow disease progression despite the persistence of the underlying genetic defect. The patient had symptomatic hypotension that limited its continuation. Pathogenic variants in COQ8B (also known as ADCK4) impair CoQ10 biosynthesis and cause steroid-resistant nephrotic syndrome, often progressing to kidney failure. CoQ serves as an electron carrier in the mitochondrial electron transport chain, transferring electrons between enzymes involved in cellular energy production. Podocytes are highly energy-dependent cells that rely heavily on oxidative phosphorylation, such that CoQ deficiency results in impaired oxidative phosphorylation, increased reactive oxygen species generation, and progressive podocyte injury and loss.8,20 The temporal association with response upon starting finerenone and loss of response upon discontinuation strongly generate a strong hypothesis for finerenone role in CoQ-associated FSGS. Further studies are needed to confirm this in larger patient cohorts and define its role in hereditary podocytopathies. In conclusion, in this genetically confirmed case of COQ8B-associated FSGS, finerenone therapy was associated with attenuation of kidney function decline and partial stabilization of proteinuria. This report supports further investigation of mineralocorticoid receptor antagonists and trajectory-based outcome measures in hereditary podocytopathies.